Why the study?
The study was conducted to investigate the hypothesis that the cardiac spinal afferent reflex plays a critical role in the development of cardiorenal syndrome type 2.
Does cardiac afferent ablation by resiniferatoxin or renal denervation improve cardiac function, renal function, and long-term survival in rats with a myocardial infarction model of chronic heart failure?
Does cardiac afferent ablation by resiniferatoxin or renal denervation improve cardiac function, renal function, and long-term survival in rats with a myocardial infarction model of chronic heart failure?
Cardiac afferent ablation and renal denervation show promise as neuromodulation therapies for improving cardiorenal outcomes in a rat model of heart failure.
May improve cardiorenal outcomes via CSAR ablation in experimental CHF; leaves open translation to human CRS2.
Cardiorenal syndrome type 2 (CRS2) is defined as a chronic cardiovascular disease, usually chronic heart failure (CHF), resulting in chronic kidney disease. We hypothesized that the cardiac spinal afferent reflex (CSAR) plays a critical role in the development of CRS2. Our data suggest that cardiac afferent ablation by resiniferatoxin not only improves cardiac function but also benefits the kidneys and increases long-term survival in the myocardial infarction model of CHF. We also found that renal denervation has a similar reno-protective effect in CHF rats. We believe this novel work contributes to the development of a unique neuromodulation therapy to treat CHF patients.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: